| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
Multiple targets including estrogen receptors (ERα, ERβ), inflammatory mediators, and cancer cell signaling pathways. 26-Deoxycimicifugoside, as a cycloartane-type triterpenoid glycoside, may exhibit estrogenic activity by binding to estrogen receptors. It may have anti-inflammatory effects by inhibiting the production of pro-inflammatory mediators. Anticancer activity may involve inhibition of cell proliferation and induction of apoptosis. The compound's mechanism of action may involve modulation of various signaling pathways.
|
|---|---|
| ln Vitro |
26-Deoxycimicifugoside exhibits biological activities typical of Cimicifuga triterpenoids, including potential estrogenic, anti-inflammatory, and anticancer effects. It may bind to estrogen receptors and modulate estrogen signaling. The compound may inhibit the production of inflammatory mediators in activated immune cells. Anticancer activity may be observed in various cancer cell lines. The compound's specific in vitro activities would depend on the concentrations tested and the assay systems used. Further studies are needed to fully characterize its activity profile.
|
| ln Vivo |
In vivo studies of 26-deoxycimicifugoside are limited. As a constituent of Cimicifuga species (black cohosh), it may contribute to the pharmacological effects of black cohosh extracts, which have been used for menopausal symptoms, including hot flashes and mood disturbances. The compound's estrogenic, anti-inflammatory, and neuroprotective effects suggest potential benefits in various disease models. Further studies are needed to characterize its specific in vivo activities.
|
| Enzyme Assay |
Non-cell-based assays for 26-deoxycimicifugoside include estrogen receptor binding assays using radiolabeled estradiol. Anti-inflammatory activity can be assessed by measuring inhibition of COX-2, LOX, or cytokine production in enzyme assays. Antioxidant activity can be assessed using DPPH, ABTS, or FRAP assays. Standard analytical methods including HPLC, NMR, and mass spectrometry are used for compound characterization.
|
| Cell Assay |
Cell-based assays for 26-deoxycimicifugoside use various cell lines to assess its biological activities. Estrogen receptor activity is assessed using MCF-7 breast cancer cells (ER-positive) or reporter gene assays with an estrogen response element (ERE)-luciferase construct. Macrophage cell lines (e.g., RAW 264.7) are stimulated with LPS and treated with the compound, and inflammatory mediators in culture supernatant are measured. Cancer cell lines are treated with the compound, and cell viability (MTT), apoptosis (Annexin V/PI), and cell cycle progression are assessed.
|
| Animal Protocol |
In vivo studies of 26-deoxycimicifugoside are limited. Based on its biological activities, potential animal models include: ovariectomized rat models for estrogenic effects; carrageenan-induced paw edema for anti-inflammatory evaluation; and tumor xenograft models for anticancer evaluation. Standard protocols for these models involve administration of the compound followed by measurement of relevant endpoints.
|
| ADME/Pharmacokinetics |
26-Deoxycimicifugoside has a molecular formula of C₃₇H₅₄O₁₀ and a molecular weight of approximately 658.82 g/mol. It is a cycloartane-type triterpenoid glycoside found in Cimicifuga species (black cohosh). The compound is soluble in organic solvents such as DMSO and methanol. It should be stored as a powder at -20°C for up to 3 years or in solvent at -80°C for 1 year. It is intended for research use only.
|
| Toxicity/Toxicokinetics |
Specific toxicity data for 26-deoxycimicifugoside are limited. Cimicifuga triterpenoids are generally considered to have low toxicity. However, comprehensive toxicological studies have not been reported. Standard laboratory safety practices should be followed when handling this compound, including the use of personal protective equipment. It is intended for research use only.
|
| References | |
| Additional Infomation |
26-Deoxycipridin has been reported to be detected in Asian cohosh (Actaea asiatica), white cohosh (Actaea racemosa), and simplex cohosh (Actaea simplex), and relevant data are available. See also: Black cohosh (partial).
26-Deoxycimicifugoside is a naturally occurring cycloartane-type triterpenoid glycoside found in Cimicifuga species (black cohosh). Black cohosh has been used in traditional medicine for menopausal symptoms, including hot flashes, mood disturbances, and sleep disorders. Triterpenoid glycosides from Cimicifuga have been reported to exhibit various biological activities, including estrogenic, anti-inflammatory, anticancer, and neuroprotective effects. 26-Deoxycimicifugoside is used as a reference standard for the identification and quantification of Cimicifuga constituents and for research purposes. It is for research use only. |
| Molecular Formula |
C37H54O10
|
|---|---|
| Molecular Weight |
658.82
|
| Exact Mass |
658.372
|
| CAS # |
214146-75-5
|
| PubChem CID |
72941763
|
| Appearance |
White to off-white solid
|
| Density |
1.34±0.1 g/cm3(Predicted)
|
| Melting Point |
260-262 °C
|
| LogP |
3.63
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
47
|
| Complexity |
1410
|
| Defined Atom Stereocenter Count |
17
|
| SMILES |
O1C2(C3([H])C(C([H])([H])[H])(C([H])([H])O2)O3)C([H])([H])C([H])(C([H])([H])[H])C2([H])C1([H])C([H])([H])C1(C([H])([H])[H])C2(C([H])([H])[H])C([H])(C([H])([H])C23C1=C([H])C([H])([H])C1([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])(C([H])([H])C([H])([H])C21C3([H])[H])OC1([H])C([H])(C([H])(C([H])(C([H])([H])O1)O[H])O[H])O[H])OC(C([H])([H])[H])=O
|
| InChi Key |
PBKJAWKRZRAQQO-YTGDHQJGSA-N
|
| InChi Code |
InChI=1S/C37H54O10/c1-18-12-37(30-33(6,47-30)17-43-37)46-21-13-32(5)23-9-8-22-31(3,4)24(45-29-28(41)27(40)20(39)15-42-29)10-11-35(22)16-36(23,35)14-25(44-19(2)38)34(32,7)26(18)21/h9,18,20-22,24-30,39-41H,8,10-17H2,1-7H3/t18-,20-,21+,22+,24+,25-,26+,27+,28-,29+,30-,32+,33-,34-,35-,36+,37+/m1/s1
|
| Chemical Name |
[(1R,1'S,3'R,4S,4'R,5R,5'R,6'R,10'S,12'S,16'R,18'S,21'R)-1,4',6',12',17',17'-hexamethyl-18'-[(2S,3R,4S,5R)-3,4,5-trihydroxyoxan-2-yl]oxyspiro[3,6-dioxabicyclo[3.1.0]hexane-4,8'-9-oxahexacyclo[11.9.0.01,21.04,12.05,10.016,21]docos-13-ene]-3'-yl] acetate
|
| Synonyms |
26-Deoxycimicifugoside
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.5179 mL | 7.5893 mL | 15.1787 mL | |
| 5 mM | 0.3036 mL | 1.5179 mL | 3.0357 mL | |
| 10 mM | 0.1518 mL | 0.7589 mL | 1.5179 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
